News Category
Regentis Biomaterials is developing GelrinC, an off-the-shelf hydrogel implant designed to regenerate knee cartilage, offering a potential alternative...
American Fusion Inc. has advanced its Texatron Fusion Engine program into active testing, achieving peak confinement pressures of approximately 100,00...
The Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference is set to provide a platform for emerging and under-covered companies to...
SuzieQ Holdings Inc. will be featured at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference, underscoring its role in build...
A new study confirms that treating selected emergency room patients while seated rather than waiting for a bed can significantly reduce wait times, po...
Helus Pharma reports progress in its Phase 3 pivotal trials for HLP003 in major depressive disorder, with topline data expected in Q4 2026, and advanc...
Helus Pharma's appointment of veteran biopharmaceutical leader Michael Halstead as CEO signals strategic focus on advancing its lead candidate HLP003 ...
Ocumetics Technology Corp. has completed a $2.5 million tranche of its private placement, bringing total proceeds to $2.95 million to fund its first-i...
Shareholders of VERAXA Biotech AG approved key proposals to enhance corporate flexibility, supporting its long-term growth strategy for antibody-based...
VERAXA Biotech has advanced its bispecific antibody-drug conjugate program VXA-222, leveraging OmniAb's discovery technologies to target solid tumors ...
Gerresheimer has commenced operations at a new, sustainable plant in Zhenjiang Dagang, China, doubling its production capacity for glass primary packa...
Darwin AG has officially changed its name to Novogenia AG, aligning the corporate identity with its core operating brand Novogenia GmbH to enhance mar...
NanoViricides (NYSE American: NNVC) progresses its oral gummies formulation of NV-387 toward a Phase II trial for the Bundibugyo ebolavirus outbreak i...
Redwood AI Corp. has been included in the CSE25 Index, reflecting its growth and potentially attracting more institutional and retail investors.
Helus Pharma announced fiscal 2026 financial results, highlighting that its Phase 3 APPROACH trial for HLP003 in major depressive disorder has surpass...
The article discusses the limitations of existing multiple sclerosis treatments and highlights Quantum BioPharma’s Lucid-MS, a novel drug candidate th...
The $410 billion drug delivery market offers a cost-effective strategy to enhance existing oncology drugs, with Oncotelic Therapeutics' Deciparticle p...
Quantum BioPharma's Lucid-MS, a first-in-class non-immunomodulatory neuroprotective therapy for multiple sclerosis, is set to enter Phase 2 trials aft...
VERAXA Biotech announced new in vitro proof-of-concept data for its BiTAC-ADC platform, which demonstrated selective killing of breast cancer cells wh...
Redwood AI Corp. is highlighted as a company to watch for its AI-powered platforms that aim to speed up chemistry research and development in pharmace...
NanoViricides announced approval from the Democratic Republic of Congo's Pillar Committee to proceed with a Phase II clinical trial of its oral antivi...
Helus Pharma's participation in the H.C. Wainwright conference highlights its progress in developing novel serotonergic agonists for mental health con...
Onco-Innovations Limited has initiated process development and scale-up for its drug candidate ONC010, a key step toward IND-enabling studies and firs...
Quantum BioPharma's LUCID-MS program aims to address the unmet need for myelin repair in multiple sclerosis, supported by a favorable safety profile i...
NeuroOne Medical Technologies will present at the Planet MicroCap Las Vegas 2026 Conference, providing updates on its OneRF platform and commercializa...
GeoVax CEO David Dodd comments on recent pharmaceutical industry acquisitions, emphasizing the growing recognition of vaccine innovation, manufacturin...
Quantum BioPharma's lead drug candidate Lucid-MS targets nerve damage in multiple sclerosis, while its commercial product unbuzzd accelerates alcohol ...
Helus Pharma, a clinical-stage pharmaceutical company developing proprietary serotonergic agonists for mental health conditions, announced its partici...
TransCode Therapeutics has begun a Phase 2a trial of TTX-MC138 in colorectal cancer patients with minimal residual disease, aiming to reduce recurrenc...
NanoViricides announces its broad-spectrum antiviral NV-387 may be evaluated for the Bundibugyo Ebola outbreak, as no approved therapies exist for thi...
SureNano Science Ltd. is advancing GEP-44, a novel GLP-1 peptide for obesity, positioning itself as an agile player in the booming GLP-1 therapy marke...
Oncotelic Therapeutics integrates 28 million scientific abstracts into its PDAOAI platform, positioning itself to compete with big pharma in the rapid...
Telomir Pharmaceuticals announced peer-reviewed preclinical data showing Telomir-Zn improves survival and reduces oxidative stress in a Wilson's disea...
The FDA's non-objection to protocol amendments for Lantern Pharma's Phase 2 HARMONIC trial clarifies the regulatory path for LP-300 in never-smokers w...
NanoViricides emphasizes the potential of its broad-spectrum antiviral candidate NV-387 as a pandemic preparedness tool during the ongoing Bundibugyo ...
Quantum BioPharma reported that its collaborative multiple sclerosis imaging study with Massachusetts General Hospital has reached midpoint enrollment...
LIXTE Biotechnology announced first-quarter 2026 progress including expansion of its ovarian cancer trial for LB-100 and growth at its Liora Technolog...
Dogwood Therapeutics announced Phase 2b data for Halneuron expected fall 2026 and FDA clearance for SP16 Phase 1b trial, with cash runway into Q4 2026...
Advancements in blood-brain barrier penetration, such as Oncotelic's intranasal delivery system, are poised to transform CNS therapeutics by enabling ...
Silo Pharma announced a strategic initiative to explore ibogaine-based therapeutics for traumatic brain injury and related conditions, filing a provis...
Three fatalities from hantavirus on the MV Hondius cruise ship highlight the risks of this little-known infection and the importance of diagnostic sys...
NanoViricides' broad-spectrum antiviral NV-387 gains FDA Orphan Drug Designation for measles, positioning it for accelerated development and market ex...
VolitionRx announced a technical milestone in detecting nucleosomes from capillary blood in sepsis patients using a lateral flow finger-prick prototyp...
Helus Pharma collaborates with TARA Mind and VETS to accelerate recruitment for its Phase 3 depression trial, addressing veteran mental health needs i...
Ventripoint Diagnostics announced that its strategic partner Lishman Global has submitted the VMS+ 4.0 system to China's NMPA for regulatory approval,...
Formycon AG will publish its 2025 annual results on April 22, 2026, followed by a conference call, and has planned participation in several internatio...
Helus Pharma announced the appointment of Dr. Ken Kramer as senior vice president of medical affairs, bringing over 20 years of neuroscience leadershi...
GeoVax announced its 2025 financial results and progress toward a Phase 3 trial for its MVA-based mpox/smallpox vaccine, GEO-MVA, which aims to addres...
